Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

AP Singh, A Biswas, A Shukla, P Maiti - Signal transduction and …, 2019 - nature.com
The application of nanomedicines is increasing rapidly with the promise of targeted and
efficient drug delivery. Nanomedicines address the shortcomings of conventional therapy, as …

Chitosan in nasal delivery systems for therapeutic drugs

L Casettari, L Illum - Journal of Controlled Release, 2014 - Elsevier
There is an obvious need for efficient and safe nasal absorption enhancers for the
development of therapeutically efficacious nasal products for small hydrophilic drugs …

Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity

YSR Elnaggar, SM Etman, DA Abdelmonsif… - Journal of …, 2015 - Elsevier
Piperine (PIP) is a phytopharmaceutical with reported neuroprotective potential in
Alzheimer's disease (AD). Oral PIP delivery suffers from its hydrophobicity and pre-systemic …

Potential of chitosan and its derivatives for biomedical applications in the central nervous system

DD Ojeda-Hernández, AA Canales-Aguirre… - … in Bioengineering and …, 2020 - frontiersin.org
It is well known that the central nervous system (CNS) has a limited regenerative capacity
and that many therapeutic molecules cannot cross the blood brain barrier (BBB). The use of …

Interests of chitosan nanoparticles ionically cross-linked with tripolyphosphate for biomedical applications

L Bugnicourt, C Ladavière - Progress in polymer science, 2016 - Elsevier
The process of ionic gelation is one of the easiest ways to develop chitosan nanoparticles
reported so far in the literature. Its success is mainly due to its one-shot synthesis, and to the …

Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform

M Pinto, V Silva, S Barreiro, R Silva, F Remião… - Ageing Research …, 2022 - Elsevier
The discovery of effective drugs for the treatment of neurodegenerative disorders (NDs) is a
deadlock. Due to their complex etiology and high heterogeneity, progresses in the …

The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer's disease: therapeutic implications and future …

MC Jurcău, FL Andronie-Cioara, A Jurcău, F Marcu… - Antioxidants, 2022 - mdpi.com
Alzheimer's disease (AD), the most common form of dementia, has increasing incidence,
increasing mortality rates, and poses a huge burden on healthcare. None of the currently …

Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation …

S Cunha, CP Costa, JA Loureiro, J Alves, AF Peixoto… - Pharmaceutics, 2020 - mdpi.com
Rivastigmine is a drug commonly used in the management of Alzheimer's disease that
shows bioavailability problems. To overcome this, the use of nanosystems, such as …

Ellagic acid-loaded, tween 80-coated, chitosan nanoparticles as a promising therapeutic approach against breast cancer: In-vitro and in-vivo study

H Kaur, S Ghosh, P Kumar, B Basu, K Nagpal - Life Sciences, 2021 - Elsevier
Aims Among polyphenolic phytoconstituents with anticancer properties, Ellagic acid (EA) is
widely reported for its translational potential in vitro but efficient in vivo delivery of EA has …

Overcoming the blood-brain barrier: Functionalised chitosan nanocarriers

AE Caprifico, PJS Foot, E Polycarpou, G Calabrese - Pharmaceutics, 2020 - mdpi.com
The major impediment to the delivery of therapeutics to the brain is the presence of the
blood-brain barrier (BBB). The BBB allows for the entrance of essential nutrients while …